![]() ![]() Small-molecules inhibiting this receptor potentiate the tumor-killing activity of the immune system. GPR174 is one of the 54 orphan GPCRs unlocked by Omeros. Starting with our compounds against GPR174, a novel immuno-oncology target, we look forward to continuing to develop important GPCR-focused drugs for the benefit of patients worldwide.” Collectively, we are building a deep and impressive pipeline that includes our proprietary GPCR program. ![]() “Each Omeros employee, particularly the members of the GPCR team, shares in this recognition. “All of us at Omeros are immensely proud to have received this award,” said Dr. It’s fitting that Omeros has now been recognized with one of the highest research awards in the pharmaceutical industry for its discoveries leading to the opening of 54 orphan GPCRs to drug discovery.” “Omeros has one of the premier GPCR teams in the world, having significantly advanced the GPCR field including being the first to describe the full complement of human and mouse non-sensory GPCRs. “This award – North America’s highest accolade in pharmaceutical research – recognizing Omeros and its scientists is well-deserved,” said Linda Buck, Ph.D., a 2004 Nobel Laureate in Physiology or Medicine for her discoveries in the olfactory system, including hundreds of sensory GPCRs. By contributing an additional 54 GPCRs to pharmaceutical drug discovery and development, Omeros is expected to improve existing therapeutic approaches and to allow for the development of wholly new treatments for diseases and disorders that currently have none. In the same period that the Omeros team identified surrogate ligands for 54 orphan GPCRs, the collective global output, including those from all other pharmaceutical companies and academic institutions, yielded ligands for only 8 such receptors. Global efforts to identify ligands for these receptors have been a significant challenge. While orphan GPCRs are extremely valuable, their biological significance cannot be easily translated into clinical utility due to technical limitations resulting from their respective lack of ligands. At least 50% of non-sensory receptors with established ligands are each targeted by one or more approved drugs or drugs in clinical trials. GPCRs are the preeminent drug targets, accounting for more than one-third of currently marketed drugs. George and Brian O’Dowd of the University of Toronto, who share the award with the Omeros team. These inventions were based on a method first developed by professors Susan R. Using this approach, the Omeros team identified surrogate ligands for 54 orphan GPCRs. Specifically, the technology allows high-throughput identification from drug libraries of functionally active compounds, or surrogate ligands, for “orphan” G protein-coupled receptors (GPCRs), which have no previously known ligands. ![]() The 2019 prize recognizes a breakthrough technology for making accessible to drug discovery an entire class of recalcitrant pharmaceutical targets. The most prestigious award in the field of Canadian pharmaceutical research and innovation, it is referred to as the Nobel Prize of pharmaceutical research. Demopulos, M.D., chairman and chief executive officer––have been named as recipients of the 2019 Prix Galien Canada Research Award. Gaitanaris, M.D., Ph.D., chief scientific officer, and Gregory A. Omeros Corporation (Nasdaq: OMER) today announced that three of its scientists––Alexander Gragerov, Ph.D., associate vice president of research, George A. Prestigious Prize Conferred for GPCR Program Discoveries. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |